炎症性肠病发作患者中非艰难梭菌细菌感染罕见
该回顾性研究分析了2011年11月19日至2014年6月30日期间9247例炎症性肠病患者中1345例接受粪便细菌检测者的资料,非艰难梭菌细菌感染检出率不足3%。感染后1年,非艰难梭菌细菌感染患者缓解率(89%)高于艰难梭菌感染患者(55%)和粪便检测阴性患者(63%),P=0.04。
要点
- 炎症性肠病发作患者中非艰难梭菌细菌感染检出率低于3%。
- 感染后1年缓解率:非艰难梭菌细菌感染89% vs 艰难梭菌感染55% vs 粪便阴性63%,P=0.04。
- 各组住院、急诊就诊或手术干预无差异。
核心结论
- 在炎症性肠病发作患者中,接受检测者非艰难梭菌细菌感染检出率低于3%。
- 感染后1年,非艰难梭菌细菌感染患者缓解比例高于艰难梭菌感染患者。
研究设计与样本
- 回顾性研究,纳入2011年11月19日至2014年6月30日期间就诊的炎症性肠病患者。
- 9247例炎症性肠病患者中,1345例(50%溃疡性结肠炎,50%克罗恩病)接受了粪便样本细菌病原体PCR或培养检测。
- 每例肠道感染患者按年龄(粪便检测时相差5岁以内)、性别和炎症性肠病亚型匹配2例炎症性肠病发作且粪便检测阴性的患者(非感染对照)和2例炎症性肠病合并艰难梭菌感染患者(艰难梭菌感染对照)。
- 随访至感染缓解后1年或健康记录中末次随访日期。
主要发现
- 溃疡性结肠炎患者:296例的339次粪便PCR检测中3次阳性(0.88%);418例的486次粪便培养中12次阳性(2.5%)。
- 克罗恩病患者:311例的355次粪便PCR检测中1次阳性(0.28%);413例的496次粪便培养中9次阳性(1.8%)。
- 19例感染后随访患者中,9例(47%)需要升级炎症性肠病治疗,最常见为加用免疫调节剂(5例)或生物制剂(3例);艰难梭菌感染对照为34%,非感染对照为66%,P<0.001。
- 感染后1年缓解比例:非艰难梭菌细菌感染患者89%,艰难梭菌感染患者55%,粪便检测阴性患者63%,P=0.04。
- 各组住院、急诊就诊或手术干预无差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Clostridium difficile infection (CDI) causes flares in patients with inflammatory bowel disease (IBD). We investigated the frequency and outcomes of non-CDI bacterial enteric infections in symptomatic patients with IBD. METHODS: We performed a retrospective study of patients with ulcerative colitis (UC) or Crohn's disease (CD) from whom stool samples were collected and analyzed by PCR or culture for bacterial pathogens (Campylobacter jejuni or C coli, Salmonella species, Shigella species, enteroinvasive Escherichia coli, shiga toxin-producing E coli, or Yersinia species) from November 19, 2011, through June 30, 2014. Patients were excluded if they had nonbacterial infections or no symptoms. Data were collected from medical records on IBD duration, treatment, age at diagnosis, and presence of concurrent CDI. Patients were followed for 1 year after the date of infection resolution or until date of last follow-up in the health record. Each patient with an enteric infection was matched with 2 patients with IBD flares and negative results from stool tests (non-infected control) and 2 patients with IBD and CDI (CDI control), adjusted for age (within 5 years at the time of stool test), sex, and IBD subtype. Outcome measures included IBD therapy escalation and hospitalization. RESULTS: Of 9247 patients with IBD seen during the study period, stool samples were tested from 1345 patients (50% with UC and 50% with CD). There were 3 positive results (detection of bacterial pathogens) from 339 PCR analyses of stool samples from 296 patients with UC (0.88%) and 12 positive results from 486 cultures of stool samples from 418 patients with UC (2.5%). There was 1 positive result from 355 PCR analyses of stool samples from 311 patients with CD (0.28%) and 9 positive results from 496 cultures of stool samples from 413 patients with CD (1.8%). Of the 19 patients followed beyond infection, 9 patients required escalation of their IBD therapy (47%)-most commonly addition of an immunomodulator (5 patients) or a biological agent (3 patients)-compared with 34% of CDI controls and 66% of non-infected controls (P < .001). Higher proportions of patients with non-CDI bacterial infections were in remission 1 year after their infection (89%) than patients with CDI (55%) or negative results of stool tests (63%; P = .04). We did not observe differences in hospitalization, emergency department visits, or surgical interventions among groups. CONCLUSIONS: In a retrospective study of patients with an IBD flare, we detected non-CDI bacterial infections in fewer than 3% of those who were tested. Higher proportions of patients with non-CDI bacterial infections were in remission in the year after their infection than patients with CDI.
引用
- Hanada Y, Khanna S, Loftus EV, et al. Non-Clostridium difficile Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2017. PMID: 29037938. doi:10.1016/j.cgh.2017.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。